Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 312

1.

Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers.

Tang P, Wang X, Schiffhauer L, Wang J, Bourne P, Yang Q, Quinn A, Hajdu SI.

Ann Clin Lab Sci. 2006 Winter;36(1):16-22.

PMID:
16501232
[PubMed - indexed for MEDLINE]
2.

Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.

Steinman S, Wang J, Bourne P, Yang Q, Tang P.

Ann Clin Lab Sci. 2007 Spring;37(2):127-34.

PMID:
17522367
[PubMed - indexed for MEDLINE]
3.

Expression patterns of ER-alpha, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ.

Tang P, Wang X, Schiffhauer L, Wang J, Bourne P, Yang Q, Quinn A, Hajdu S.

Ann Clin Lab Sci. 2006 Spring;36(2):137-43.

PMID:
16682508
[PubMed - indexed for MEDLINE]
4.

Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease.

Celis JE, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans-Wielenga V, Rank F, Moreira JM.

Mol Oncol. 2007 Dec;1(3):321-49. doi: 10.1016/j.molonc.2007.09.004. Epub 2007 Sep 25.

PMID:
19383306
[PubMed - indexed for MEDLINE]
Free Article
5.

Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer.

Bryan BB, Schnitt SJ, Collins LC.

Mod Pathol. 2006 May;19(5):617-21.

PMID:
16528377
[PubMed - indexed for MEDLINE]
Free Article
6.

Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.

Hanley K, Wang J, Bourne P, Yang Q, Gao AC, Lyman G, Tang P.

Hum Pathol. 2008 Mar;39(3):386-92. doi: 10.1016/j.humpath.2007.07.007. Epub 2008 Jan 9.

PMID:
18187183
[PubMed - indexed for MEDLINE]
7.

Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.

Baqai T, Shousha S.

Histopathology. 2003 May;42(5):440-7.

PMID:
12713620
[PubMed - indexed for MEDLINE]
8.

Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.

Ottesen GL.

APMIS Suppl. 2003;(108):1-67. Review.

PMID:
12874968
[PubMed - indexed for MEDLINE]
9.

Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.

van der Groep P, van Diest PJ, Menko FH, Bart J, de Vries EG, van der Wall E.

J Clin Pathol. 2009 Oct;62(10):926-30. doi: 10.1136/jcp.2009.065524. Epub 2009 Jun 18.

PMID:
19541683
[PubMed - indexed for MEDLINE]
10.

Mammary stem cells and breast cancer--role of Notch signalling.

Farnie G, Clarke RB.

Stem Cell Rev. 2007 Jun;3(2):169-75. Review.

PMID:
17873349
[PubMed - indexed for MEDLINE]
11.

Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications.

Hilson JB, Schnitt SJ, Collins LC.

Am J Surg Pathol. 2009 Feb;33(2):227-32. doi: 10.1097/PAS.0b013e318180431d.

PMID:
18936688
[PubMed - indexed for MEDLINE]
12.
13.

Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ?

Tan PH, Aw MY, Yip G, Bay BH, Sii LH, Murugaya S, Tse GM.

Am J Surg Pathol. 2005 May;29(5):625-32.

PMID:
15832086
[PubMed - indexed for MEDLINE]
14.

Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.

Dabbs DJ, Chivukula M, Carter G, Bhargava R.

Mod Pathol. 2006 Nov;19(11):1506-11. Epub 2006 Aug 25.

PMID:
16941011
[PubMed - indexed for MEDLINE]
Free Article
15.

Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.

Castro NP, Osório CA, Torres C, Bastos EP, Mourão-Neto M, Soares FA, Brentani HP, Carraro DM.

Breast Cancer Res. 2008;10(5):R87. doi: 10.1186/bcr2157. Epub 2008 Oct 17.

PMID:
18928525
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.

Hurd TC, Sait S, Kohga S, Winston J, Martinick M, Saxena R, Lankes H, Markus G, Harvey S, Gibbs JF.

Ann Surg Oncol. 2007 Nov;14(11):3117-24. Epub 2007 Aug 16.

PMID:
17701256
[PubMed - indexed for MEDLINE]
17.

Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias.

Bratthauer GL, Moinfar F, Stamatakos MD, Mezzetti TP, Shekitka KM, Man YG, Tavassoli FA.

Hum Pathol. 2002 Jun;33(6):620-7.

PMID:
12152161
[PubMed - indexed for MEDLINE]
18.

Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.

Rabban JT, Koerner FC, Lerwill MF.

Hum Pathol. 2006 Jul;37(7):787-93. Epub 2006 May 26.

PMID:
16784976
[PubMed - indexed for MEDLINE]
19.

P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.

Paredes J, Lopes N, Milanezi F, Schmitt FC.

Virchows Arch. 2007 Jan;450(1):73-80. Epub 2006 Nov 23.

PMID:
17123107
[PubMed - indexed for MEDLINE]
20.

S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.

Emberley ED, Alowami S, Snell L, Murphy LC, Watson PH.

Breast Cancer Res. 2004;6(4):R308-15. Epub 2004 Apr 26.

PMID:
15217497
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk